External broker reports(aggregated public sources), Motilal Oswal Financial Services Limited

Motilal Oswal

External broker reports(aggregated public sources)

Motilal Oswal Financial Services Limited

Motilal Oswal Financial Services Limited is an Indian diversified financial services firm offering a range of financial products and services. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

Equity Bottom-Up

Clean Science and Technology / Equity Bottom-Up

<ul><li>CLEAN’s R&amp;D, focused on innovation and sustainability, achieved key milestones in FY24, including the commercialization of HALS series and the development of pharma intermediates.</li><li>Currently, there are 10 new molecules in progress, which should drive future growth in the pharmaceuticals, polymers, and sustainable agrochemicals segments of the company.</li><li>Clean Fino Chem (CFCL), a wholly owned subsidiary of CLEAN, is scaling up HALS production (current total capacity of 10.5ktpa) and expanding its capacity through Unit-4 and Unit-3 to meet rising global demand in pharmaceuticals, agrochemicals, and polymers.</li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

CLEAN’s R&amp;D, focused on innovation and sustainability, achieved key milestones in FY24, including the commercialization of HALS series and the development of pharma intermediates.Currently, there are 10 new molecules in progress, which should drive future growth in the pharmaceuticals, polymers, and sustainable agrochemicals segments of the company.Clean Fino Chem (CFCL), a wholly owned subsidiary of CLEAN, is scaling up HALS production (current total capacity of 10.5ktpa) and expanding its capacity through Unit-4 and Unit-3 to meet rising global demand in pharmaceuticals, agrochemicals, and polymers.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Clean Science & Technology - CFCL – Future Growth Engine

External broker reports(aggregated public sources), HDFC Securities

HDFC Securities

HDFC securities is the best online trading platform for stocks, IPOs, mutual fund in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

<ul><li>We maintain SELL on Clean Science and Technology (CSTL) with a price target of INR 1,037 (WACC 11%, terminal growth 6%), owing to (1) slower-than-expected ramp-up in hindered amine light stabilizers (HALS) and (2) entry of domestic competitors in mono methyl ether of hydroquinone (MEHQ) manufacturing</li><li>We believe CSTL has an import substitution opportunity in HALS</li><li>However, the upcoming capacity augmentation in HALS by competitors and muted demand growth shall remain challenges to growth in HALS revenue</li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

We maintain SELL on Clean Science and Technology (CSTL) with a price target of INR 1,037 (WACC 11%, terminal growth 6%), owing to (1) slower-than-expected ramp-up in hindered amine light stabilizers (HALS) and (2) entry of domestic competitors in mono methyl ether of hydroquinone (MEHQ) manufacturingWe believe CSTL has an import substitution opportunity in HALSHowever, the upcoming capacity augmentation in HALS by competitors and muted demand growth shall remain challenges to growth in HALS revenueContent is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Clean Science and Technology: HALS Expansion: CSTL's Strategic Leap.

<ul><li>We maintain SELL on Clean Science and Technology (CSTL) with a price target of INR 1,026 (WACC 11%, terminal growth 6%), owing to (1) slower-than-expected ramp-up in hindered amine light stabilisers (HALS) (2) entry of domestic competitor in mono methyl ether of hydroquinone (MEHQ) manufacturing and (3) lower offtake of performance chemicals</li><li>Gross profit margin and EBITDA margin are expected to fall by 520/340 bps by FY26 from 65/43% in FY23</li><li>Global giants are augmenting the capacities of HALS and intermediates of HALS.</li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

We maintain SELL on Clean Science and Technology (CSTL) with a price target of INR 1,026 (WACC 11%, terminal growth 6%), owing to (1) slower-than-expected ramp-up in hindered amine light stabilisers (HALS) (2) entry of domestic competitor in mono methyl ether of hydroquinone (MEHQ) manufacturing and (3) lower offtake of performance chemicalsGross profit margin and EBITDA margin are expected to fall by 520/340 bps by FY26 from 65/43% in FY23Global giants are augmenting the capacities of HALS and intermediates of HALS.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Clean Science and Technology: Margin to Decline, Valuation Expensive. Maintain SELL

<ul><li>CLEAN reported a beat on our EBITDA estimate, while gross margin expanded to 62.5% (est. 59.2%).</li><li>EBITDAM was flat at 39.4% (v/s 39% in 1QFY23). The Performance and FMCG Chemicals segment performed better QoQ, led by increased realizations across all products.</li><li>Input prices remain volatile and a short-term concern for the company.</li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

CLEAN reported a beat on our EBITDA estimate, while gross margin expanded to 62.5% (est. 59.2%).EBITDAM was flat at 39.4% (v/s 39% in 1QFY23). The Performance and FMCG Chemicals segment performed better QoQ, led by increased realizations across all products.Input prices remain volatile and a short-term concern for the company.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Clean Science and Technology - Remains Confident in the New Series of Products

External broker reports(aggregated public sources), Nirmal Bang

Nirmal Bang

A Relationship Beyond Broking

Nirmal Bang, one of the leading stock broking companies in India, caters to retail and institutional clients by offering them a range of financial products and services, including equities, derivatives, commodities, currency derivatives, mutual funds, IPOs, insurance, depository services and PMS.

Nirmal Bang is drawn from a diversity of professional backgrounds, and blend of experience, skill and dedication is shared with its clients. Nirmal Bang emphasizes adequate, thorough research local and world-wide developments, balancing these with the astute discovery of intrinsic values, synergies and growth. The aim is simply to help the investors to maximize their returns.

<div><div><div><div><ul><li>We are comfortable with everything but valuation: Implementation of sustainable chemistry practices and ongoing process improvement (to cut down or eliminate the use of toxic materials such as KSMs, Efflux) is the need of the hour.</li><li>While many companies are increasingly taking initiatives on that front, CLEAN is the pioneer in the same and is the classic example of why the chemical industry should shift to these practices in order to protect the environment without compromising their operational performance.</li><li>Hence, valuation premium vis-à-vis like-to-like peers as well as chemicals industry should persist, in our view.</li></ul></div></div></div></div><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

We are comfortable with everything but valuation: Implementation of sustainable chemistry practices and ongoing process improvement (to cut down or eliminate the use of toxic materials such as KSMs, Efflux) is the need of the hour.While many companies are increasingly taking initiatives on that front, CLEAN is the pioneer in the same and is the classic example of why the chemical industry should shift to these practices in order to protect the environment without compromising their operational performance.Hence, valuation premium vis-à-vis like-to-like peers as well as chemicals industry should persist, in our view.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Clean Science & Technology - 4Q Ahead of Estimates; Continues to Gain Customer

India

Clean Science and Technology Limited is an Indian manufacturer of functionally critical specialty chemicals, utilizing innovative and sustainable green chemistry processes. The company's products, including MEHQ, BHA, Anisole, and Guaiacol, cater to industries such as pharmaceuticals, agrochemicals, FMCG, and personal care. It was founded in 2003 and is headquartered in Pune, India.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Clean Science and Technology (CLEAN IN)

Clean Science & Technology - CFCL – Future Growth Engine

CLEAN’s R&D, focused on innovation and sustainability, achieved key milestones in FY24, including the commercialization of HALS series and the...

Motilal Oswal

Clean Science and Technology: HALS Expansion: CSTL's Strategic Leap.

However, the upcoming capacity augmentation in HALS by competitors and muted demand growth shall remain challenges to growth in HALS revenue

HDFC Securities

Clean Science and Technology: Margin to Decline, Valuation Expensive. Maintain SELL

Gross profit margin and EBITDA margin are expected to fall by 520/340 bps by FY26 from 65/43% in FY23. Global giants are augmenting the capacities...

HDFC Securities

Clean Science and Technology - Remains Confident in the New Series of Products

EBITDAM was flat at 39.4% (v/s 39% in 1QFY23). The Performance and FMCG Chemicals segment performed better QoQ, led by increased realizations...

Motilal Oswal

Clean Science & Technology - 4Q Ahead of Estimates; Continues to Gain Customer

Clean Science & Technology’s (CLEAN) 4QFY22 EBITDA came in ~14% ahead of our estimate mainly on account of strong revenue growth across...

Nirmal Bang

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)